BRIEF

on Biocon

Biocon's Pertuzumab Receives EU Marketing Authorization

Biocon Limited's pertuzumab biosimilar, Pebrilzo®, has been granted marketing authorization by the European Commission for the treatment of HER2-positive breast cancer across multiple stages. This makes it the first biosimilar approved under the European Medicines Agency's (EMA) new tailored clinical approach. The decision supports Biocon's focus on addressing evolving patient and healthcare needs, reinforcing its growing oncology portfolio.

Shreehas Tambe, CEO & Managing Director of Biocon, highlighted the significance of this approval, marking it as a key regulatory milestone that strengthens the company's commitment to providing high-quality, affordable therapies. The authorization follows a positive opinion from the CHMP in September 2026.

The biosimilar, indicated for use with trastuzumab and chemotherapy, showcases extensive similarity to the reference product without clinically meaningful differences. Its approval adds to Biocon's efforts in oncology, offering options for sustainable healthcare systems across Europe.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Biocon news